OrthoPediatrics (KIDS) came out with a quarterly loss of $0.30 per share versus the Zacks Consensus Estimate of a loss of $0.42. This compares to loss of $0.29 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 28.57%. A quarter ago, it was expected that this maker of orthopedic devices would post a loss of $0.28 per share when it actually produced a loss of $0.23, delivering a surprise of 17.86%.Over the last four quarters, the ...

OrthoPediatrics Corp. Reports First Quarter 2024 Financial Results and Increases Full Year 2024 Revenue Guidance First Quarter 2024 Revenue Increased 41% Year-over-Year WARSAW, Ind., May 6, 2024 -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced its financial results for the first quarter ended March 31, 2024. First Quarter 2024 and Business Highlights • Helped nearly 28,000 children in ...

公司经营风险 - 公司可能受到信贷协议限制，影响未来融资和业务扩张[207] - 公司的有效税率可能会波动，可能会有超过应计金额的税务义务[208] - 公司拥有联邦、州和外国净经营亏损结转额，可能会受到所有权变更的限制[210] - 公司的商誉、无形资产和固定资产可能会受到潜在减值影响[212] - 公司长期增长取决于产品开发和商业化能力，未能成功可能影响竞争力[215] - 公司面临市场份额增长挑战，需要成功商业化产品并满足市场需求[216] - 公司竞争激烈，如果无法成功竞争，销售和运营结果可能受到负面影响[223] - 公司必须保持足够的库存，可能会导致资源消耗和库存减值费用[229] - 公司提供免费借出的仪器套装可能触犯某些联邦和州欺诈和滥用法律[231] - 公司可能通过收购、投资新的或互补性的业务、产品或技术、许可第三方的产品或技术或其他战略联盟来实现业务增长[233] - 潜在和已完成的收购、战略投资、许可和其他联盟涉及诸多风险，包括整合收购或许可的技术、产品或业务操作的困难，以及与收购或战略联盟相关的未预期成本[235] - 公司可能无法成功通过战略交易实现增长，这取决于公司能否成功识别、谈判、完成和整合合适的目标业务、技术或产品，并获得必要的融资[236] - 外国收购涉及独特风险，包括与不同文化、语言和法律法规环境的运营整合相关的风险[237] - 公司可能选择发行普通股作为收购、投资或战略联盟的对价，这可能 dilute 股东的所有权[238] - 收购新的或互补性业务、产品或技术具有固有风险，无法保证任何收购或投资将成功或不会对公司产生重大不利影响[239] 市场环境风险 - 公司可能难以获得领先医院和关键意见领袖的支持，这可能使产品难以成为标准治疗方式并获得市场认可[240] - 公司寻求与受尊敬的骨科医生和医疗人员保持密切合作关系，以协助产品研发和改进[242] - 如果骨科医生无法安全和适当地使用公司产品，或者公司无法对骨科医生进行安全和适当使用产品的培训，公司可能无法实现预期的增长[247] 法律合规风险 - 公司缺乏支持其产品具有卓越临床结果的长期数据，这可能限制销售[264] - 美国医疗保险支付情况对公司产品销售有重要影响[267] - 政府医疗计划和第三方支付者对新技术的成本进行严格审查[269] - 第三方支付者定期更新报销金额和决定报销金额的方法[270] - 美国医疗保险政策的变化可能影响私人医疗保险支付[271] - 美国医疗保险制度改革可能限制公司产品的覆盖范围和报销[272] - 国外市场的医疗保险制度对公司产品销售产生影响[273] - 政府和商业第三方支付者未提供足够的覆盖范围和报销可能影响公司产品的市场性[275] - 公司面临违反FCPA和其他禁止不当支付的法律的风险，可能导致巨额罚款、制裁和业务受损[297] 财务风险 - 美元升值可能导致国际市场竞争力下降或成本增加，未进行任何对冲交易[299] - 公司需承担作为上市公司的重大成本，管理层需要投入大量时间进行公共公司合规计划[304] - 公司需维护有效的财务报告内部控制，任何控制不足可能影响投资者对公司的信心[306] - 公司成为加速报告人，将增加法律和财务合规成本，可能导致股价下跌[308]

Call Start 08:00 January 1, 0000 9:04 AM ET OrthoPediatrics Corp (NASDAQ:KIDS) Q4 2023 Earnings Conference Call March 07, 2024 08:00 AM ET Company Participants Trip Taylor - Investor Relations David Bailey - President and CEO Fred Hite - Chief Operating Officer and CFO Conference Call Participants Matthew O'Brien - Piper Sandler Rick Wise - Stifel Ryan Zimmerman - BTIG Dave Turkaly - Citizens JMP Samuel Brodovsky - Truist Securities Operator Good morning and welcome to OrthoPediatrics Corporation's Fourth Q ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission file number: 001-38242 OrthoPediatrics Corp. (Exact name of registrant as specified in its charter) Delaware 26-1761833 (Sta ...

OrthoPediatrics Corp (NASDAQ:KIDS) Q3 2023 Earnings Conference Call November 7, 2023 8:00 AM ET Company Participants Trip Taylor - Investor Relations David Bailey - President and Chief Executive Officer Fred Hite - Chief Operating and Financial Officer Conference Call Participants Matthew O’Brien - Piper Sandler Rick Wise - Stifel Ryan Zimmerman - BTIG Samuel Brodovsky - Truist Securities Operator Good morning, and welcome to the OrthoPediatrics Corporation Third Quarter 2023 Earnings Conference Call. [Oper ...

OrthoPediatrics Corp. (NASDAQ:KIDS) Q2 2023 Earnings Conference Call August 1, 2023 8:00 AM ET Company Participants Trip Taylor - Investor Relations, Gilmartin Group David Bailey - President and Chief Executive Oficer Fred Hite - Chief Financial Officer and Chief Operating Officer Conference Call Participants Ryan Zimmerman - BTIG Matthew O'Brien - Piper Sandler David Saxon - Needham and Company Dave Turkaly - JMP Securities Sam Brodovsky - Truist Securities Operator Good morning, and welcome to OrthoPediat ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission file number: 001-38242 OrthoPediatrics Corp. (Exact name of registrant as specified in its charter) Delaware 26-1761833 (State or ...

OrthoPediatrics Corp. (NASDAQ:KIDS) Q1 2023 Results Conference Call May 2, 2023 8:00 AM ET Company Participants Trip Taylor - IR, Gilmartin Group David Bailey - President and CEO Fred Hite - COO and CFO Conference Call Participants Rick Wise - Stifel Ryan Zimmerman - BTIG Mike Matson - Needham & Company Sam Brodovsky - Truist Operator Good morning and welcome to OrthoPediatrics Corporation’s First Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode. We will be fac ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission file number: 001-38242 OrthoPediatrics Corp. (Exact name of registrant as specified in its charter) Delaware 26-1761833 (State o ...